ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Bertagnolli: Why Brigham Stopped Making Morcellation Available Outside Of A Registry Trial

July 4, 2014

October issue of Business & Regulatory Report included.

November 5, 2004

House Committee Investigates Marketing Practices Of Amgen And J&J For ESAs.

April 4, 2008

NCI-Approved Clinical Trials

November 24, 2006

Dipersio Is Chief Of Oncology At Washington University.

July 14, 2000

Henderson, Weinstein, Jukes to Present AACR Award Lectures

March 6, 1987